IHI Corporation

IHI Corporation

13.57
EUR
-0.23
(-1.68%)
18.45BMarket Cap
Nov 04Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1,265.77
1,347.44
1,424.6
1,375.09
1,471.8
1,373.52
1,186.13
1,070.18
1,115.37
1,277.72
1,248.59
1,535.43
1,550.43
- -
Basic EPS, GAAP
32.16
8.41
1.41
4.85
7.67
36.93
7.7
12.59
62.82
42.07
-64.4
106.41
151.88
- -
Free Cash Flow per Basic Share
-14.85
-7.42
39.36
10.28
36.66
42.6
-27.99
-20.27
65.22
-7.99
1.06
110.79
27.92
- -
Dividend per Share
7.07
12.81
8.55
0.01
4.28
8.56
10.13
2.87
4.32
11.44
14.3
14.3
20.03
- -
Book Value per Share
320.12
320.74
295.22
295.11
301.19
285.1
269.3
289.31
360.9
407.21
354.88
454.65
615.23
615.23
Tangible Book Value per Share
281.11
274
249.32
257.04
267.85
139.25
143.92
167.01
240.87
284.25
228.97
324.09
482.6
482.6
Basic Weighted Avg Shares
1,030
1,080
1,081
1,081
1,081
1,080
1,065
1,040
1,052
1,059
1,059
1,060
1,060
1,060
Sales/Revenue/Turnover
1,304,038
1,455,844
1,539,388
1,486,332
1,590,333
1,483,442
1,263,178
1,112,906
1,172,904
1,352,940
1,322,591
1,626,831
1,643,402
- -
Operating Margin (%)
4.09
4.34
1.43
3.19
4.54
5.56
3.79
2.51
6.95
6.06
-5.3
8.82
10.07
- -
Depreciation Expense
53,099
57,451
63,103
63,417
63,244
61,613
77,261
80,185
84,193
70,934
75,828
76,765
86,822
- -
Net Income, GAAP
33,133
9,082
1,529
5,247
8,291
39,889
8,204
13,093
66,065
44,545
-68,214
112,740
160,992
- -
Effective Tax Rate (%)
41.32
75.25
- -
46.43
29.32
34.86
54.59
38.61
21.36
25.41
- -
15.3
10.93
- -
Profit Margin (%)
2.54
0.62
0.1
0.35
0.52
2.69
0.65
1.18
5.63
3.29
-5.16
6.93
9.8
- -
Working Capital
174,952
257,801
217,737
197,594
181,819
54,014
41,108
181,872
250,317
254,143
159,644
184,338
275,113
275,113
LT Debt
209,840
275,494
260,053
246,277
235,747
344,177
343,211
429,928
393,272
362,392
379,713
371,212
366,797
366,797
Total Equity
362,555
359,595
333,359
337,630
350,217
338,885
306,040
327,727
407,039
456,251
402,268
508,660
681,531
681,531
Return on Invested Capital (%)
4.48
2.06
- -
3.58
7.38
7.09
2.46
1.84
6.86
6.38
- -
11.88
13.06
- -
Return on Capital (%)
4.85
1.68
- -
0.35
0.77
4.89
0.8
1.34
7.24
5.19
- -
12.09
15.02
- -
Return on Common Equity (%)
10.44
2.62
0.46
1.64
2.57
12.6
2.79
4.51
19.35
10.95
-16.9
26.29
28.39
- -

Capital Structure

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
ST Debt
- -
216,928
123,096
LT Borrowings
- -
263,196
255,981
LT Finance Leases
- -
101,058
110,816
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,060
1,060
1,060
Market Capitalization
- -
- -
3,383,672

Working Capital

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
Total Current Assets
- -
1,396,214
1,451,394
Cash, Cash Equivalents & STI
- -
105,620
159,184
Accounts Receivable, Net
- -
528,462
575,965
Inventories
- -
524,589
504,223
Total Current Liabilities
- -
1,174,593
1,176,281
Payables & Accruals
- -
- -
- -
ST Debt
- -
216,928
123,096
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.41%
16.98%
33.99%
Free Cash Flow
962.24%
1,923.55%
-74.79%
Net Income, GAAP
55.89%
-20.72%
42.8%
Sales/Revenue/Turnover
1.26%
8.5%
1.02%
Total Cash Common Dividend
2,900.37%
56.82%
40.07%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
298,457
171,853
396,353
455,928
1,322,591
2025
- -
- -
- -
- -
1,626,831
2026
- -
- -
- -
- -
1,643,402

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.28
-135.2
26.4
39.06
-64.4
2025
- -
- -
- -
- -
106.41
2026
- -
- -
- -
- -
151.88

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7.16
-0.03
7.17
-0.02
14.3
2025
- -
- -
- -
- -
14.3
2026
- -
- -
- -
- -
20.03

Company Description

CEO
Hiroshi Ide
Full Time Employees
26,224
Sector
Producer manufacturing
Industry
Industrial machinery
Address
Toyosu IHI Building Tokyo TY Japan 135-8710
IPO Date
May 16, 1949
Website
ihi.co.jp
Business
IHI Corporation IHI Corporation (7013.T) operates as a comprehensive heavy industries group, designing, manufacturing, and providing engineering solutions across four primary segments: Resources, Energy and Environment; Social Infrastructure; Industrial Systems and General-Purpose Machinery; and Aero Engine, Space and Defense. The company offers gas turbines, power systems and plants, boilers, nuclear energy equipment including small modular reactors (SMR), ammonia-fueled engines and combustion technologies, LNG terminals, bridges, tunnels, water gates, disaster management systems, large steel structures, marine propulsion systems, vehicular turbochargers, centrifugal compressors such as the new TRZ series, materials handling equipment, aero engines for civil and defense applications, rocket motors, space utilization systems, unmanned assets, and traffic control systems; it serves power generation, infrastructure, manufacturing, aerospace, and defense sectors with a focus on decarbonization solutions like sustainable aviation fuel (SAF), green ammonia production, storage, and utilization, as well as biomethane production. Founded in 1853 and headquartered in Tokyo, Japan, IHI conducts global operations primarily in Asia including Japan and China, with projects and subsidiaries spanning Europe, North America, Southeast Asia, and other regions, employing approximately 28,000 people under President Hiroshi Ide. Recent developments include the establishment of IHI Infrastructure Systems Co., Ltd. in 2025 through integration of bridge, disaster prevention, and water gate businesses for enhanced competitiveness; full-scale launch of a new civil aero engine maintenance facility; partnerships such as MoUs with SpaceData Inc. for satellite data utilization, ICEYE for Earth observation satellite constellations to bolster national security, Vopak for an ammonia terminal joint venture in Japan, GE Vernova for ammonia gas turbine combustion testing, and Indonesian partners for Southeast Asia's first green ammonia trial at a coal-fired plant; awards for ammonia burner inventions and combustion demonstrations; divestitures including the transfer of shares in Niigata Transys and Meisei Electric, and the materials handling business of IHI Transport Machinery to Tadano; participation as engine contractor in the Japan-UK-Italy next-generation fighter program under GCAP; facility expansions for SMR equipment and defense production; and introduction of restricted stock remuneration for executives alongside a stock split.

Company News

  • EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe

  • Ihi Corp (OTCMKTS:IHICY) Shares Shorted: Short Interest Up 338.5% in September

  • IHI (OTCMKTS:IHICY) Sees Strong Trading Volume – Should You Buy?

  • IHI Appoints Dr. Amar Shah as Chief Scientific Officer

  • IHI (OTCMKTS:IHICY) and Allison Transmission (NYSE:ALSN) Head to Head Comparison

  • IHI: Limited Upside With Unfavorable Risk-Reward

  • IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group

  • IHI: Pressured Consumers, Unclear Healthcare Policy, Weak Price Action

  • Comparing Atlas Copco (OTCMKTS:ATLKY) & IHI (OTCMKTS:IHICY)

  • Tennant (NYSE:TNC) versus IHI (OTCMKTS:IHICY) Financial Survey

  • GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe

  • IHI: Pullback Creates A Buying Opportunity In High-Growth MedTech

  • Head to Head Contrast: IHI (OTCMKTS:IHICY) and Middleby (NASDAQ:MIDD)

  • X-energy, IHI Corporation Partner to Advance U.S.-Japan SMR Supply Chain Development

  • China Adds 20 Japanese Firms to Export Control List, Markets React

  • IHI (OTCMKTS:IHICY) Stock Price Up 6.2% – Here’s What Happened

  • IHI Corporation (IHICY) Q3 2026 Earnings Call Prepared Remarks Transcript

  • SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments

  • DNOW (NYSE:DNOW) & IHI (OTCMKTS:IHICY) Head to Head Survey

  • PreciseOnco research consortium awarded EUR 14.9 million IHI grant to drive breakthroughs in precision cancer treatment